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Many azole-resistant (AR) clinical isolates of Candida albicans display increased expression of the drug
transporters CDR1 and CDR2. In this study, we evaluate the molecular mechanisms that contribute to the
maintenance of constitutively high CDR1 transcript levels in two matched pairs of azole-susceptible (AS) and
AR clinical isolates of C. albicans. To address this, we use reporter constructs of GFP and lacZ fused either to
the CDR1 promoter (PCDR1-GFP/lacZ; transcriptional fusion) or to the CDR1 open reading frame (PCDR1-
CDR1-GFP/lacZ; translational fusion) integrated at the native CDR1 locus. It is observed that expression of the
two reporter genes as a transcriptional fusion in the AR isolates is higher than that in matched AS isolates.
However, the difference in the reporter activity between the AS and AR isolates is even greater for the
translational fusions, indicating that the sequences within the CDR1 coding region also contribute to its
increased expression in AR isolates. Further analysis of these observations by transcription run-on assays
demonstrated a 5- to 7-fold difference in the transcription initiation rates for the AR isolates from those for
their respective matched AS isolates. Measurement of mRNA stability showed that the half-life of CDR1mRNA
in the AR isolates was threefold higher than that in the corresponding AS isolates. Our results demonstrate
that both increased CDR1 transcription and enhanced CDR1 mRNA stability contribute to the overexpression
of CDR1 in AR C. albicans isolates.
Resistance of the human fungal pathogen Candida albicans
to azole antifungals is often caused by increased expression of
genes encoding multidrug efflux pumps, the ATP-binding cas-
sette transporter genes CDR1 and CDR2 and/or the major
facilitator gene CaMDR1 (1, 7, 23, 29, 34, 36, 37, 38, 44, 45, 46).
However, the molecular mechanisms leading to the constitu-
tive overexpression of efflux pump-encoding genes in drug-
resistant, clinical C. albicans isolates are only beginning to be
understood. In particular, the regulation of CDR1 expression
has been studied by many groups (2, 3, 4, 5, 10, 11, 17, 20, 32).
Various unrelated stresses, including elevated temperature or
the presence of drugs and steroids, induce a transient tran-
scriptional activation of CDR1 in drug-susceptible C. albicans
strains (20). Several cis elements in the CDR1 upstream region
that affect basal as well as induced CDR1 expression have been
identified. Puri et al. (32) identified four upstream activating
sequences and four upstream repressing sequences in the 5
noncoding region of CDR1. A basal regulatory element and a
negative regulatory element, in the proximal region of the
promoter, have also been characterized and implicated in the
basal expression of CDR1 (10, 11). A specific steroid-respon-
sive region in the distal part of the CDR1 promoter, consisting
of two progesterone-responsive sequences and one -estradiol-
responsive sequence, has been shown to contribute exclusively
to steroid responsiveness of CDR1 (17). Another basal expres-
sion element in the CDR1 upstream region and a drug re-
sponse element (DRE), which is present in the upstream re-
gion of CDR1 and CDR2, have been identified by de Micheli et
al. (5). The DRE was found to mediate both the transient
upregulation of CDR1 and CDR2 by steroid hormones and
drugs and their constitutive overexpression in a resistant strain
(5).
Coste et al. identified a transcription factor, TAC1 (transcrip-
tional activator of CDR genes), that binds to the DRE in the
CDR1 and CDR2 promoters (3). Inactivation of TAC1 resulted in
the loss of fluphenazine-induced upregulation of CDR1 and
CDR2, with little impact on basal expression levels, and also
abrogated the constitutive overexpression of these efflux pumps in
a drug-resistant strain (3, 4, 5). CaNdt80p, a homolog of the
meiosis-specific transcription factor Ndt80p of Saccharomyces
cerevisiae, is another positive regulator of CDR1. Deletion of
CaNDT80 abolished the induced expression of CDR1 and in-
creased the sensitivity of C. albicans to antifungals (2). Interest-
ingly, the global repressor CaTup1p acts as a negative regulator of
CDR1 expression (26, 48).
Although transcriptional regulation is considered to be the
key step accounting for complex basal and induced patterns of
CDR1 expression, the possibility of posttranscriptional control
of CDR1 expression, which could also affect drug resistance,
still remains to be explored. The large amounts of Cdr1p,
which correlate with high CDR1 mRNA levels, in azole-resis-
tant (AR) C. albicans strains not only may be due to increased
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CDR1 transcription but could also be caused by increased
stability of its mRNA and protein. It is therefore of interest to
compare the following: (i) CDR1 transcription initiation rates,
(ii) CDR1 mRNA stability, and (iii) Cdr1 protein stability in
drug-susceptible and CDR1-overexpressing, drug-resistant C.
albicans strains. In this study, we have addressed these issues
by exploiting two pairs of matched azole-susceptible (AS) and
CDR1-overexpressing, AR isolates. By using transcriptional
and translational reporter gene fusions, transcriptional run-on
(TRO), thiolutin, and cycloheximide chase assays, we demon-
strate that CDR1 overexpression in C. albicans is caused by an
increase in its transcriptional initiation rate and by increased
mRNA stability.
MATERIALS AND METHODS
Materials. Medium chemicals were obtained from HiMedia (Mumbai, India).
Restriction endonuclease, DNA-modifying enzymes, ultra-pure deoxyribonucle-
otides (dATP, dGTP, dCTP, and dTTP) for PCR, and ribonucleotides (ATP,
CTP, GTP, and UTP) for TRO were purchased from New England Biolabs
(NEB, Inc.). Thiolutin (CP-4092) was a generous gift from Pfizer, Inc., Groton,
CT. Radiolabeled [5,6-3H]uridine, [-32P]dATP, and [-32P]UTP were obtained
from Amersham Biotech and Bhabha Atomic Research Center, India. Polyclonal
anti-Cdr1p antibody was custom synthesized from Covance Research Products,
Inc., PA. Oligonucleotides used were commercially synthesized from Sigma-
Aldrich. All molecular biology-grade chemicals used in this study were obtained
from Sigma Chemical Co. (St. Louis, MO), and routinely used chemicals (Tris,
sodium chloride, glycine, potassium acetate, sodium carbonate, magnesium chlo-
ride, sodium hydroxide pellets, methanol, glacial acetic acid, urea, sodium do-
decyl sulfate [SDS], formamide, and ethanol) were obtained from Qualigens and
Merck, Mumbai, India.
Bacterial and yeast strains and growth media. Escherichia coli DH5 was used
as a host for plasmid constructions and propagation. C. albicans strains used in
this study are listed in Table 1. C. albicans strains were maintained on yeast
extract-peptone-dextrose (YEPD) medium. All strains were stored as frozen
stocks with 15% glycerol at 80°C. Before each experiment, cells were freshly
revived on YEPD plates from this stock.
Plasmid construction. All primers and plasmids used in this study are listed in
Table 2. Plasmids pCPL51 and pCPG3, harboring the PCDR1-lacZ and PCDR1-
GFP transcriptional fusions, were constructed as follows. A CDR1 promoter
fragment was first amplified from genomic DNA of isolate Gu5 with the primers
CDR1F and CDR1R, digested at the introduced ApaI and XhoI sites, and
substituted for the CDR1 promoter fragment in the previously described plasmid
pCPL1 (11) to generate pCPL5. A CDR1 downstream fragment was then am-
plified from genomic DNA of strain SC5314 with the primers CDR29 and
CDR30. The PCR product was digested at the introduced PstI and SacII sites
and ligated with the PstI/SacII-digested plasmid vectors pCPL5 and pCPG1 (11)
to generate pCPL51 and pCPG3, respectively. Notably, plasmid pCPG1 harbors
the CDR1 promoter isolated from SC5314 genomic DNA, which has been used
in our previous studies (11). The SC5314-derived CDR1 promoter showed se-
quence differences from the CDR1 promoters in the matched AS or AR isolates
(at nucleotide positions 21, 150, 171, 215, 238, 315, 368, 381,
418, and 455 relative to the transcription start point) which have been used
in this study (unpublished observation). These differences, however, did not
affect the -galactosidase reporter activity of integrated cassettes derived either
from pCPL1 (11), which harbors the SC5314 CDR1 promoter, or from pCPL4 or
pCPL5, which harbor the Gu4- or Gu5-derived CDR1 promoter, respectively
(data not shown). Plasmid pCPG2, which contains the GFP reporter gene fused
in frame with the last codon of the CDR1 open reading frame (ORF), was
constructed as follows. The C-terminal region of CDR1 was amplified from
SC5314 genomic DNA with the primers CDR32 and CDR31, digested at the
introduced KpnI and BamHI sites, and ligated together with a BamHI-PstI
fragment from pADH1G3 (14) containing GFP, the ACT1 transcription termi-
nation sequence, and the CaSAT1 marker into the KpnI/PstI-digested pCPL51.
To generate pCPL52, in which the lacZ reporter gene instead of GFP is fused in
frame to the CDR1 ORF, the C-terminal part of CDR1 was PCR amplified from
SC5314 genomic DNA with the primers CDR32 and CT-CDR1-R-RML, di-
gested at the introduced KpnI and XhoI sites, and ligated into the KpnI/XhoI-
digested pCPL51. To ensure in-frame translational fusion of the CDR1 ORF
with lacZ, pCPL62 was generated, in which an additional “A” in pCPL52 before
the lacZ ATG was removed by site-directed mutagenesis employing the A-del
pCPL52-F and A-del pCPL52-R primers. All constructs were confirmed by
appropriate restriction digestion analysis and by sequencing. The flanking CDR1
sequences in all of these plasmids served for genomic integration of the reporter
fusions at the native CDR1 locus of clinical C. albicans isolates, and the dominant
CaSAT1 marker (33) was used to select nourseothricin-resistant (Nour) trans-
formants. Briefly, for the electroporation, 5 l (approximately 1 g) of the
linearized DNA fragments were mixed with 40 l of electrocompetent cells (33)
and electroporated using a Bio-Rad Genepulser XL system (0.2-cm cuvette, 1.5
kV). After electroporation, C. albicans transformants were washed with 1 ml of
1 M sorbitol, resuspended in 1 ml YEPD medium, incubated for 3 to 4 h with
shaking at 30°C prior to plating on YEPD plates containing 200 g/ml of
nourseothricin, and grown at 30°C (33). Nour transformants were picked up after
24 h of growth, and single-copy integration of each construct at the desired locus
was confirmed by Southern hybridization with gene-specific probes (data not
shown).
Fluorescence microscopy and flow cytometry of the cells. The strains were
grown overnight in YEPD liquid medium, and aliquots were spotted on micro-
scope slides. Fluorescence microscopy was performed with a Zeiss Axiolab mi-
croscope equipped for epifluorescence microscopy with a 50-W mercury high-
pressure bulb and the Zeiss fluorescein-specific filter set 09. Imaging scans were
acquired with an Argon laser of 488-nm wavelength and corresponding filter
settings for green fluorescent protein (GFP) and parallel transmission images.
For confocal microscopy, the cells were placed on glass slides and directly viewed
with a Bio-Rad confocal microscope (Radiance 2100, AGR, 3Q/BLD; Bio-Rad,
United Kingdom) under a 100 oil immersion objective (41). Fluorescence-
TABLE 1. C. albicans strains used
Strain Description Reference
Gu4 Fluconazole-susceptible clinical
isolate
Franz et al. (6)
Gu4G1 PCDR1-GFP integrated at
CDR1 locus
This study
Gu4G2 PCDR1-CDR1-GFP integrated
at CDR1 locus
This study
Gu4L2 PCDR1-lacZ integrated at CDR1
locus
This study
Gu4L3 PCDR1-CDR1-lacZ integrated at
CDR1 locus
This study
Gu5 Fluconazole-resistant clinical
isolate
Franz et al. (6)
Gu5G1 PCDR1-GFP integrated at
CDR1 locus
This study
Gu5G2 PCDR1-CDR1-GFP integrated
at CDR1 locus
This study
Gu5L2 PCDR1-lacZ integrated at CDR1
locus
This study
Gu5L3 PCDR1-CDR1-lacZ integrated at
CDR1 locus
This study
DSY294 Fluconazole-susceptible clinical
isolate
Sanglard et al. (38)
DSY294G1 PCDR1-GFP integrated at
CDR1 locus
This study
DSY294G2 PCDR1-CDR1-GFP integrated
at CDR1 locus
This study
DSY294L2 PCDR1-lacZ integrated at CDR1
locus
This study
DSY294L3 PCDR1-CDR1-lacZ integrated at
CDR1 locus
This study
DSY296 Fluconazole-resistant clinical
isolate
Sanglard et al. (38)
DSY296G1 PCDR1-GFP integrated at
CDR1 locus
This study
DSY296G2 PCDR1-CDR1-GFP integrated
at CDR1 locus
This study
DSY296L2 PCDR1-lacZ integrated at CDR1
locus
This study
DSY296L3 PCDR1-CDR1-lacZ integrated at
CDR1 locus
This study
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activated cell sorter (FACS) analysis was performed using a FACSCalibur flow
cytometer (Becton-Dickinson Immunocytometry Systems, San Jose, CA)
equipped with an argon laser emitting at 488 nm. Fluorescence was measured on
the FL1 fluorescence channel equipped with a 530-nm bandpass filter. A total of
20,000 events were counted at the low flow rate. Fluorescence data were col-
lected using logarithmic amplifiers. Data analysis was performed using CellQuest
software (Becton Dickinson Immunocytometry Systems). The mean fluorescence
intensity was calculated using the histogram statistics program.
Immunodetection of GFP in AS and AR reporter strains. Purified plasma
membrane (PM) and crude-extract fractions of GFP reporter strains were pre-
pared as described previously (13, 41). For Western blots, membranes were
incubated with a 1:5,000 dilution of monoclonal anti-GFP antibody (JL-8) (BD
Biosciences, Clontech) or a 1:1,000 dilution of polyclonal anti-Pma1p (plasma
membrane ATPase) antibody. Immunoreactivity was detected using horseradish
peroxidase-labeled secondary antibodies at a dilution of 1:5,000 (goat antimouse
antibody for GFP and goat antirabbit antibody for Pma1p) using the enhanced
chemiluminescence assay system (ECL kit; Amersham Biosciences, Arlington
Heights, IL).
-Galactosidase assays. -Galactosidase assays were performed using dupli-
cate samples of cells from three independent experiments as described previously
(11, 21, 42). -Galactosidase activity was determined by the standard equation
(11, 21, 42) and is expressed in Miller units per mg of protein (Miller units are
arbitrary units): -galactosidase activity (Miller units) 	 [OD420  1,000]/
[OD600  t  v], where t is time of reaction expressed in min, v is volume of
culture used in the assay, expressed in ml, and OD420 and OD600 are optical
densities at 420 and 600 nm, respectively.
TRO analysis. TRO experiments were performed as described previously (8,
24) with the following modifications. Cells were grown at 30°C in YEPD with
agitation until the culture reached an OD600 of 1.0. An aliquot of yeast cells
(6  108 per ml) was used to perform TRO. The cells were centrifuged for 5 min
at 4,000  g and resuspended in 5 ml of cold TMN (10 mM Tris, 100 mM NaCl,
5 mM MgCl2; pH 7.4). The cells were again centrifuged for 5 min at 4,000  g,
and the cell pellet was resuspended in 900 l of sterile cold diethyl pyrocarbonate
(DEPC)-treated water. Next, the cell suspension was transferred to a fresh
microcentrifuge tube containing 50 l of 10% N-lauryl sarcosine sodium sulfate
(sarkosyl) and was incubated for 20 min on ice. After the permeabilization step,
cells were recovered by low-speed centrifugation at 6,000 rpm for 2 min at 4°C
and the supernatant was removed. In vivo transcription was reinitiated by resus-
pending the permeabilized cell fraction in 120 l of 2.5 transcription buffer (50
mM Tris-HCl [pH 7.7], 500 mM KCl, 80 mM MgCl2), 16 l of AGC mix (10 mM
TABLE 2. Plasmids and oligonucleotides used
Name Description Source (reference) or sequencea
Plasmids
pBS-KS() Plasmid vector used for cloning purpose Stratagene
pACT1 Plasmid harboring ACT1 gene Gift from Anand Bachhawat
pSAT1 Plasmid harboring caSAT1 marker Reuss et al. (33)
pLACZ6 Plasmid harboring lacZ reporter gene Gaur et al. (11)
pADH1G3 Plasmid harboring GFP reporter gene and caSAT1
marker
Hiller et al. (14)
pCPG1 Plasmid harboring PCDR1-GFP fusion for ACT1
locus integration
Gaur et al. (11)
pCPG3 Plasmid harboring PCDR1-GFP fusion for CDR1
locus integration
This study
pCPG2 Plasmid harboring CDR1-GFP fusion for CDR1
locus integration
Prasad et al. (30)
pCPL1 Plasmid harboring PCDR1-lacZ fusion for ACT1
locus integration
Gaur et al. (11)
pCPL51 Plasmid harboring PCDR1-lacZ fusion for CDR1
locus integration
This study
pCPL52 Plasmid harboring CDR1-lacZ fusion for CDR1
locus integration
This study
pCPL62 Plasmid harboring in frame CDR1-lacZ fusion for
CDR1 locus integration
This study
Oligonucleotides
CDR1F Forward primer for CDR1 promoter amplification 5-GATCGGGCCCTCGTTACTCAATAAGTAT-3
CDR1R Reverse primer for CDR1 promoter amplification 5-AGCTCTCGAGTTCTTTTTGACCTTTTAAAG-3
CDR1-F-RML Forward primer for CDR1 promoter amplification 5-GCTTCGCCTCAACTTCTTATAAAGTTTTGAAAG-3
CDR1-R-RML Reverse primer for CDR1 promoter amplification 5-CGTGGTATTCATTAATGGAATGGTTTTCTGAAG-3
CDR29 Forward primer for amplification of CDR1
downstream region
5-AATTCTGCAGTTTGTTTTTTGACATGGTGGTATC-3
CDR30 Reverse primer for amplification of CDR1
downstream region
5-TCGTGCCGCGGAACACTTTTTCTTTCTAATTATAA-3
CDR32 Forward primer for amplification of CDR1 C-
terminal region
5-ATTTGGTACCATACATTAAATTTGCTGGTGGG-3
CDR31 Reverse primer for amplification of CDR1 C-
terminal region
5-GTTTGGATCCTTTCTTATTTTTTTTCTCTCTGTTACC
C-3
CT-CDR1-R-RML Reverse primer for amplification of CDR1 C-
terminal region
5-GTTTCTCGAGTTTCTTATTTTTTTTCTCTCTGTTACC
C-3
A-del pCPL52-F Forward primer for in-frame translational fusion
of CDR1-ORF with lacZ
5-GAGAGAAAAAAAATAAGAAACTCGAGATGAACAT
GACTGAAAAAATTCAAAC-3
A-del pCPL52-R Reverse primer for in-frame translational fusion of
CDR1-ORF with lacZ
5-GTTTGAATTTTTTCAGTCATGTTCATCTCGAGTTTCT
TATTTTTTTTCTCTC-3
KM1 Forward primer for amplification of CDR1 N-
terminal region
5-CTTTTCCACTGGTAACTACT-3
KM2 Reverse primer for amplification of CDR1 N-
terminal region
5-CAATAAACCTGCTGACGAG-3
a Restriction sites introduced into the primers are underlined, while the flanking bases are written in italics.
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each of ATP, GTP, and CTP), 6 l of dithiothreitol (0.1 M), 1 U of RNase
inhibitor per l, 10 mM phosphocreatine, 1.2 g of creatine phosphokinase per
l, and 15 l of [-32P]UTP (3,000 Ci/mmol, 10 Ci/l). Cells were maintained
on ice at all times. The final volume was adjusted to 300 l with DEPC-treated
water, and the mix was incubated for 15 min at 30°C to allow transcription
elongation. The reaction was stopped by adding 1 ml of ice-cold DEPC-treated
water to the mix. Cells were recovered by centrifugation to remove nonincorpo-
rated radioactive nucleotides. Total RNA was isolated using the Trizole reagent
(Sigma) as per the manufacturer’s specifications except that 200 l of ice-cold
acid-washed 0.4- to 0.6-mm-diameter glass beads (Sigma, St. Louis, MO) were
also used for efficient and complete lysis of permeabilized cells. Isolated total
labeled RNA was again precipitated by adding 2.5 M NH4 acetate and an equal
volume of isopropanol. The mixture was stored overnight at20°C. To pellet the
RNA, tubes were centrifuged at 14,000 rpm for 15 min in the microcentrifuge.
The isopropanol was removed, and the labeled RNA pellet was washed twice
with 70% ethanol, dried, and resuspended in 100 l of DEPC-treated water. This
double precipitation of RNA was used to minimize DNA contamination. Total
extracted RNA was spectrophotometrically quantified. An aliquot was used for
specific radioactivity determination in a Tri-CARB 2900 TR liquid scintillation
analyzer (Packard instrument Co., Inc.). All of the in vivo-labeled RNA of each
isolate (2  106 to 2.5  106 cpm) was subsequently used for reverse Northern
hybridization with a dot blotted Nylon membrane (Hybond-N; Amersham
Pharmacia Biotech) containing PCR-amplified gene-specific N-terminal CDR1
sequences (nucleotides 242 to 256 from the transcription start point), plas-
mid pACT1 (positive control), and pBlueScript-KS() (negative control) as
probes, as per the manufacturer’s recommendation. Northern blots were scanned
with a phosphorimager scanner (FLA-5000 Fuji phosphorimager). Signal inten-
sities of hybridized nuclear RNA were quantified and subsequently normalized
to the actin intensities using densitometry scanning.
Thiolutin chase assay. In order to measure the CDR1 mRNA half-life, a
potent in vivo transcriptional inhibitor of C. albicans, thiolutin, was used (18, 40).
AS and AR isolates of C. albicans were incubated with an optimized concentra-
tion (40 g/ml) of thiolutin (data not shown). For this purpose, cultures were
treated with 150 M of the copper chelator bathocuprioinedisulphonic acid and
incubated at 30°C for an additional 10 min at 200 rpm. Transcription was
subsequently shut off by the addition of 150 nM of CuSO4 and 40 g/ml of
thiolutin. Addition of bathocuprioinedisulphonic acid and CuSO4 was found to
enhance the response of the cells to thiolutin (40). Briefly, 100 ml of cells were
grown to an OD600 of 1.0 at 30°C. Aliquots of cells were taken at the indicated
times after transcriptional shutoff. Total RNA was isolated using Ambion’s
RiboPure-Yeast RNA isolation kit (catalog no. 1926) as per the manufacturer’s
instructions. For Northern blots, approximately 20 g of total RNA from the
above samples was hybridized with probes derived from gene-specific sequences
of the CDR1 gene. Hybridization signal intensity was quantified with a phosphor-
imager and was normalized to the band intensity at time T0 and plotted as a line
graph.
Cycloheximide chase assay. Cycloheximide chase assays were performed as
described earlier (9) with certain modifications that included the use of an
optimized concentration of cycloheximide (16) (data not shown) and the alkaline
extraction procedure used for the preparation of crude protein extract (13).
Briefly, aliquots of mid-log-phase-grown cells were withdrawn for analysis after
translational shutoff at the indicated times and lysed in solution containing 1.85
M NaOH and 7.5% -mercaptoethanol. Crude proteins isolated were precipi-
tated with 50% trichloroacetic acid and sedimented. The sediment was resus-
pended in loading buffer (40 mM Tris-HCl [pH 6.8], 8 M urea, 5% SDS, 0.1 M
EDTA, 1% -mercaptoethanol, and 0.1 mg/ml bromophenol blue) and incu-
bated at 37°C for 10 min. Nonsolubilized material was cleared by a centrifugation
step, and solubilized proteins (approximately 20 and 30 g for AR and AS
isolates, respectively) were separated by 10% SDS-polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose membrane for Western blotting.
Immunodetected Cdr1p signal intensity was quantified with a phosphorimager
and was normalized to the band intensity at time T0 and plotted as a line graph.
RESULTS
Expression of transcriptional and translational GFP re-
porter fusions in AS and AR isolates. To analyze the molecular
basis of CDR1 upregulation in azole-resistant, clinical C. albi-
cans isolates in more detail, we employed two matched pairs of
AS and AR isolates. The resistant isolates Gu5 and DSY296,
which were obtained after fluconazole therapy for oropharyn-
geal candidiasis in two different human immunodeficiency vi-
rus-positive patients, were shown by DNA fingerprinting to be
highly related to the susceptible isolates Gu4 and DSY294,
respectively, which were recovered from earlier infection epi-
sodes in the same patients (6, 38). It was recently shown that a
mutation in the transcription factor TAC1 is responsible for
CDR1 and CDR2 upregulation in DSY296 (4). However, it has
not yet been explored if other mechanisms contribute to the
overexpression of the efflux pumps in these isolates.
We compared the expression of two different GFP reporter
fusions in these isolates, one in which GFP was expressed from
the CDR1 promoter (PCDR1-GFP) and another where GFP was
fused in frame to the last codon of the CDR1 ORF and ex-
pressed from the CDR1 promoter (PCDR1-CDR1-GFP) (see
Materials and Methods) (Fig. 1A). The reporter fusions were
integrated at the native CDR1 locus, and two transformants of
each of the four parental strains were used for further analysis.
The reporter strains were designated Gu4G1 (PCDR1-GFP)
and Gu4G2 (PCDR1-CDR1-GFP); Gu5G1 (PCDR1-GFP) and
Gu5G2 (PCDR1-CDR1-GFP); DSY294G1 (PCDR1-GFP) and
DSY294G2 (PCDR1-CDR1-GFP); and DSY296G1 (PCDR1-
GFP) and DSY296G2 (PCDR1-CDR1-GFP).
Expression of the PCDR1-GFP transcriptional and PCDR1-
CDR1-GFP translational fusions in cells grown to mid-expo-
nential phase (OD600 of1.0) was detected by epifluorescence
microscopy (Fig. 1B) and quantified by FACS analysis (Fig.
1C). As expected, the fluorescence intensities of the AR
reporter fusion strains were higher than those of the corre-
sponding AS strains (2.5-fold for Gu5G1 versus Gu4G1, 19-
fold for Gu5G2 versus Gu4G2; 6-fold for DSY296G1 versus
DSY294G1; and 80-fold for DSY296G2 versus DSY294G2),
confirming the previously reported increased CDR1 transcript
and Cdr1p protein levels in the AR isolates (4, 6, 38). Inter-
FIG. 1. Schematic depiction of GFP reporter fusion integrants and their expression in AS and AR isolates. (A) Structure of the DNA cassettes
which were used to integrate the transcriptional (PCDR1-GFP, top) and translational (PCDR1-CDR1-GFP, bottom) GFP reporter fusions into the
CDR1 locus of the clinical C. albicans isolates (middle). The CDR1 and GFP coding regions are represented by white and green arrows,
respectively, the CaSAT1 marker by the gray arrow, and the transcription termination sequence of the ACT1 gene (TACT1) by the filled circle. CDR1
upstream and downstream regions are represented by solid lines, and the CDR1 promoter (PCDR1) is symbolized by the bent arrow. Only relevant
restriction sites are shown. (B) Nomarski and corresponding fluorescence micrographs of transformants containing the chromosomally integrated
PCDR1-GFP (left) or PCDR1-CDR1-GFP (right) reporter fusion. (C) Cells of the reporter strains grown to exponential phase in YEPD medium were
diluted to a density of 2  107 cells per ml in phosphate-buffered saline (pH 7.0), and a total of 20,000 events were analyzed by flow cytometry.
The parental strains of the transformants, which do not contain GFP, were used as a negative control. The mean fluorescence intensity is shown
for each population of cells (bottom panel) after normalization with values for their corresponding negative controls. Since the normalized mean
fluorescence intensity of DSY294G2 was a negative value, we designated it “1.0” for calculating the degree of change for this particular strain.
a.u., arbitrary units.
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estingly, however, expression of the PCDR1-CDR1-GFP trans-
lational fusion resulted in much lower fluorescence than ex-
pression of the PCDR1-GFP transcriptional fusion in AS
isolates (6-fold for Gu4G2 versus Gu4G1 and 13-fold for
DSY294G2 versus DSY294G1), whereas the two types of re-
porter fusions produced comparable fluorescence in AR iso-
lates. Notably, confocal microscopy confirmed that the Cdr1p-
GFP fusion protein was correctly localized to the cell
membrane in all reporter strains expressing the translational
fusion (Fig. 2A). Immunoreactive bands of the expected sizes
were observed in whole-cell extracts and plasma membrane
preparations of the PCDR1-GFP and PCDR1-CDR1-GFP re-
porter strains, respectively, after Western immunoblotting with
an anti-GFP antibody (Fig. 2B). Additionally, the tagging of
PCDR1 and PCDR1-CDR1 with GFP did not alter the drug re-
sistance profiles of AS and AR isolates, which ruled out that
the GFP fusions caused any selective impact on Cdr1p func-
tionality for either AS or AR isolates (data not shown).
Expression of transcriptional and translational lacZ re-
porter fusions in AS and AR isolates. To rule out that the
reduced expression of the PCDR1-CDR1-GFP translational fu-
sion in AS isolates was an artifact intrinsic to the Cdr1p-GFP
fusion protein, we used codon-optimized lacZ (42) as an alter-
native reporter gene. As for GFP, transcriptional (PCDR1-lacZ)
and translational (PCDR1-CDR1-lacZ) lacZ reporter fusions
were generated and integrated at the native CDR1 locus of the
AS and AR isolates (see Materials and Methods) (Fig. 3A).
The expression of Cdr1p in the PCDR1-CDR1-lacZ construct
was unaffected by its fusion to lacZ as tested by Western
blotting with an anti-Cdr1p antibody (data not shown). Two
transformants of each parental strain containing a single copy
of the reporter fusion were used for further analysis. The
reporter strains were designated Gu4L2 (PCDR1-lacZ) and
Gu4L3 (PCDR1-CDR1-lacZ); Gu5L2 (PCDR1-lacZ) and Gu5L3
FIG. 3. Schematic depiction of lacZ reporter fusion integrants and qual-
itative and quantitative assay of -galactosidase activity in AS and AR iso-
lates. (A) Structure of the DNA cassettes which were used to integrate the
transcriptional (PCDR1-lacZ, top) and translational (PCDR1-CDR1-lacZ, bot-
tom) lacZ reporter fusions into the CDR1 locus of the clinical C. albicans
isolates (middle). The CDR1 and lacZ coding regions are represented by
white and blue arrows, respectively, the CaSAT1 marker by the gray arrow,
and the transcription termination sequence of theACT1 gene (TACT1) by the
filled circle. CDR1 upstream and downstream regions are represented by
solid lines, and the CDR1 promoter (PCDR1) is symbolized by the bent arrow.
Only relevant restriction sites are shown. (B) Transformants harboring chro-
mosomally integrated PCDR1-lacZ (transcriptional fusion, left) and PCDR1-
CDR1-lacZ (translational fusion, right) and their corresponding parental
strain (without lacZ) were streaked on minimal medium plates containing
5-bromo-4-chloro-3-indolyl--D-galactopyranoside and photographed after 3
days’ growth at 30°C. The positions of the individual strains on the plates are
shown in the scheme (middle). (C) -Galactosidase quantitative reporter
activities of each transformant were determined as described previously (11,
21, 42). The values are means
 standard deviations (indicated by the bars)
of three independent experiments with duplicate measurements of two inde-
pendent clones. Empty and filled bars indicate transcriptional (PCDR1-lacZ)
and translational fusion (PCDR1-CDR1-lacZ) transformants in both AS and
AR backgrounds.
FIG. 2. Localization of Cdr1p and immunodetection of GFP in
reporter fusion transformants. (A) Nomarski (left) and corresponding
confocal (right) pictures of the transformants harboring the chromo-
somally integrated PCDR1-CDR1-GFP (translational fusion) reporter
construct are shown which indicate the proper plasma membrane lo-
calization of chimeric Cdr1p in clinical C. albicans isolates. The cells
were viewed directly on a glass slide with a 100 oil immersion ob-
jective. (B) The Western blot analyses were done with an anti-GFP
monoclonal antibody on both the transcriptional and translational
fusion integrants. Equal loading of protein was assessed by using an
anti-Pma1p polyclonal antibody.
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(PCDR1-CDR1-lacZ); DSY294L2 (PCDR1-lacZ) and DSY294L3
(PCDR1-CDR1-lacZ); and DSY296L2 (PCDR1-lacZ) and
DSY296L3 (PCDR1-CDR1-lacZ).
Expression of the lacZ reporter gene in various strains was
assessed by comparing the intensity of the blue color produced
by cells grown on agar plates containing the indicator dye
5-bromo-4-chloro-3-indolyl--D-galactopyranoside (Fig. 3B)
and was quantified by determining -galactosidase activities in
liquid assays (Fig. 3C). The lacZ reporter study confirmed the
results obtained with GFP. Higher lacZ expression levels were
observed in transformants of the AR isolates than in transfor-
mants of the AS isolates (1.4-fold for Gu5L2 versus Gu4L2,
37-fold for Gu5L3 versus Gu4L3, 5.6-fold for DSY296L2 ver-
sus DSY294L2, and 13-fold for DSY296L3 versus DSY294L3).
In addition, while the transcriptional and translational fusions
yielded comparable activities in the AR isolates, expression of
the translational fusion was much lower than that of the tran-
scriptional fusion in the AS isolates (26-fold for Gu4L3 versus
Gu4L2 and 2-fold for DSY294L3 versus DSY294L2). Of note,
the integration of PCDR1-lacZ reporter fusion constructs at the
ectopic ACT1 locus resulted in -galactosidase activity compa-
rable to that of native CDR1 locus integrants (data not shown).
Growth phase versus -galactosidase reporter activity. To
investigate whether the observed differences in the expression
FIG. 4. -Galactosidase reporter activity of lacZ reporter fusion integrants of AS and AR isolates during growth phase. Transcriptional fusion
(PCDR1-lacZ) and translational fusion (PCDR1-CDR1-lacZ) reporter transformants of each isolates were grown from an initial OD600 of 0.1 in YEPD
broth and withdrawn at the indicated time points of growth for -galactosidase reporter activity (Fig. 4A, B, C, and D). The inset depicts growth
curves of the PCDR1-lacZ () and PCDR1-CDR1-lacZ (f) reporter transformants in AS and AR isolates. The negative-control parental strain
(without lacZ fusion constructs) reporter activity value was always below 0.5 Miller units, and it was subtracted from the reporter activity of each
corresponding transcriptional and translational fusion transformant. The values are means 
 standard deviations (indicated by the bars) for three
independent experiments with duplicate measurements of two independent clones. Gu4 transformants (A), Gu5 transformants (B), DSY294
transformants (C), and DSY296 transformants (D) were analyzed. Empty and filled bars indicate transcriptional (PCDR1-lacZ) and translational
fusion (PCDR1-CDR1-lacZ) transformants in both AS and AR backgrounds.
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of transcriptional and translational reporter gene fusions in AS
and AR isolates depended on the growth phase, we quantita-
tively monitored -galactosidase activities in the lacZ reporter
strains at various times during growth in batch cultures. As can
be seen in Fig. 4, the low reporter expression levels of the
translational PCDR1-CDR1-lacZ fusion compared with those of
the transcriptional PCDR1-lacZ fusion in the AS isolates were
observed at all growth stages (Fig. 4A and C). In contrast, both
types of reporter fusion produced comparable -galactosi-
dase activities in the AR isolates throughout growth (Fig. 4B
and D).
Taken together, exploitation of reporter fusions and their
expression analysis indicated that an increase in CDR1 expres-
sion levels in the AR isolates compared to those in the corre-
sponding AS isolates is contributed by affecting either CDR1
promoter activity, mRNA stability, translational efficiency, or
protein stability. Therefore, we performed further experiments
on native CDR1 (endogenous gene) to get a real insight into
whether transcriptional/posttranscriptional control mecha-
nisms are involved in the upregulation of CDR1 expression in
AR isolates.
Transcriptional rate for CDR1 is increased in AR isolates.
We first tested whether the transcription rate for CDR1 was
elevated in the AR isolates. For this purpose, TRO assays were
performed. Both AS and AR isolates were grown to an OD600
of 1.0, and the cells were permeabilized with the detergent
N-lauryl sarcosine sodium sulfate (sarkosyl) for the isolation of
intact nuclei (8, 24). The subsequent incubation of isolated
nuclei with transcription buffer and radiolabeled [-32P]UTP
reinitiated the transcription (see Materials and Methods). The
in vivo-labeled nascent RNAs were then used as probes in
reverse Northern hybridizations with dot blotted CDR1-spe-
cific PCR-amplified DNA. As controls, pACT1 plasmid DNA,
containing the constitutively expressed ACT1 gene, and the
empty vector pBluescript were also dotted on the membranes.
As shown in Fig. 5A and B, the AR isolates exhibited an
increased rate of transcription of CDR1 compared with that for
the AS isolates (fivefold for Gu5 versus Gu4 and sevenfold for
DSY296 versus DSY294).
CDR1 mRNA stability is increased in AR isolates. To inves-
tigate if in addition to the increased transcription rates post-
transcriptional events also contribute to the higher level of
CDR1 expression in drug-resistant strains, we determined
CDR1 mRNA stability in the AS and AR isolates. To this end,
we exploited an effective sulfur-containing purine analogue,
thiolutin, as a potent inhibitor of de novo transcription to
determine mRNA stability in C. albicans (18, 40). Thiolutin
affected [3H]uridine incorporation into nascent RNAs in a
concentration-dependent manner. About 40 g/ml of thiolutin
inhibited 95% of the [3H]uridine incorporation in total RNA
(data not shown). Methylene blue staining revealed no decline
in cell viability of AS and AR isolates treated with 40 g/ml
thiolutin, although growth was inhibited to a certain extent
(data not shown). This optimized thiolutin concentration was
subsequently used for the mRNA chase assays. Total RNA was
isolated at different time points after transcriptional inhibition
with thiolutin and analyzed by RNA gel blots (Fig. 6A). After
probing the blots with a CDR1-specific probe, hybridization
signals were quantified by densitometry scanning in a phosphor-
imager. Figure 6B depicts a typical CDR1 mRNA decay profile
FIG. 5. TRO analysis of AS and AR isolates. (A) Approximately 2 g (each) of CDR1, pACT1, and empty vector pBlueScript-KS() DNA
was blotted and immobilized on charged nylon membranes (Hybond-N; Amersham Pharmacia Biotech) using a dot blot assembly apparatus. The
blots were probed with total labeled nuclear run-on RNA as described in Materials and Methods. Hybridization signal intensities of nuclear RNA
were quantified using densitometry scanning of phosphorimages. DNA from a pBlueScript-KS() plasmid was used as a negative control for
nonspecific binding of nuclear RNA to a random DNA fragment. Signal intensities for each isolate were subtracted from the negative control
values and subsequently normalized to the intensity corresponding to their AS isolate. The AR/AS ratio is the normalized nuclear RNA intensity
between AR and AS isolates. (B) The relative intensity of CDR1 with respect to actin RNA of each isolate is plotted.
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in the AS and AR isolates over a 300-min period from one of
these experiments. CDR1 mRNA could be detected in both AS
isolates Gu4 and DSY294 at time T0, and the signal intensity
diminished progressively with time (mRNA half-life was ap-
proximately 60 min). The turnover of the CDR1 transcript
occurred much more slowly in the AR isolates Gu5 and
DSY296, with a half-life of 180 min. These results demon-
strated that CDR1 mRNA stability was increased in the AR
isolates over that in the AS isolates.
Cdr1 protein stability does not differ in AS and AR isolates.
To test whether increased protein stability might also contrib-
ute to the high Cdr1p levels in AR isolates, cycloheximide
chase assays were performed. Total crude protein extracts
were isolated at different times after treatment of the cells with
an optimized concentration (75 mM) of cycloheximide (16)
and analyzed by Western immunoblotting with a rabbit poly-
clonal anti-Cdr1p antibody. Figure 7A shows the Western blot
of the decay experiment, while Fig. 7B shows the quantitative
decay profile. The half-life of Cdr1p was similar in AS and AR
isolates and was calculated to be approximately 90 min.
DISCUSSION
In this study, we used two pairs of matched AS and AR C.
albicans clinical isolates to study the mechanisms of CDR1
overexpression in AR isolates. Our results demonstrate that
both increased transcriptional activation and enhanced mRNA
stability contribute to increased CDR1 expression in these
drug-resistant isolates. Interestingly, we found that in the AS
isolates reporter fusions with the CDR1 coding region were
expressed at lower levels than fusions in which the reporter
genes were directly fused to the CDR1 promoter, whereas in
the AR isolates the two types of reporter fusions were ex-
pressed at comparable levels. This would mean that sequences
in the CDR1 coding region can also contribute to the increased
CDR1 expression in AR isolates.
FIG. 6. CDR1 mRNA decay assay. Exponentially growing cultures of C. albicans were incubated with the optimized thiolutin concentration (40
g/ml) to inhibit ongoing in vivo transcription. Total RNA was isolated at the indicated times thereafter and fractionated on a 1% (wt/vol)
agarose–2.2 M formaldehyde denaturing gel. (A) The gel was stained with ethidium bromide before blotting to monitor equal loading of the RNA
and subsequently blotted onto a charged nylon membrane. The blot was hybridized with a CDR1-specific probe. Time points in minutes are
indicated below each phosphorimage. (B) The hybridization signals were quantified using densitometry scanning in a phosphorimager. The signal
intensity at each time point was normalized to that of time T0 (expressed as a percentage) and plotted as described in Materials and Methods. t1/2,
half-life.
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It has been shown previously that CDR1 overexpression in C.
albicans is caused by an increased CDR1 transcription rate in
AR isolates compared with that in AS isolates (24). Our TRO
experiments confirmed that the transcriptional initiation rate
from the CDR1 promoter was five- to sevenfold higher in the
AR isolates than in the AS isolates used in the present study
(Fig. 5). The CDR1 upstream region contains many sequence
elements which are involved in the regulation of CDR1 expres-
sion (5, 10, 11, 17, 32); however, no sequence differences were
found in the CDR1 upstream region of these matched pairs of
AS and AR isolates (5, 11; also unpublished observations). In
line with this, it has recently been shown that a gain-of-function
mutation in the transcription factor TAC1, which controls
CDR1 expression, causes CDR1 upregulation in the AR isolate
DSY296 (4).
In order to evaluate if, in addition to transcriptional activa-
tion of CDR1, differential mRNA and protein stability also
contribute to the enhanced Cdr1p levels in AR isolates, we
performed thiolutin and cycloheximide chase assays and ob-
served that the up-regulation of CDR1 mRNA in AR isolates
was due to an increase in the mRNA half-life (180 min),
which was approximately threefold greater than that in AS
isolates (Fig. 6). In contrast, no difference in Cdr1p protein
stability was observed between AS and AR isolates (Fig. 7).
There are examples in other organisms where overexpression
of efflux pumps can be caused by increased mRNA stability. An
increase in the mRNA half-life of MDR1 (a CDR1 homologue
in humans) has been shown to contribute to doxorubicin and
colchicine resistance in the myelogenous leukemic cell line
K562 (47). An enhanced mRNA stability of bmr3, encoding a
multidrug transporter, also leads to a multidrug-resistant
(MDR) phenotype in Bacillus subtilis (28). In addition, the
reported MDR phenotype of Entamoeba histolytica trophozo-
ites is also caused by transcriptional activation (27), as well as
an increase in mRNA stability of the EhPgp5 gene (22).
Notably, though, cis determinants located in the 3 untrans-
lated region (UTR) regulate the degradation of mRNA (35).
Among these cis elements, adenylate-uridylate-rich-element
motifs of the 3 UTR involved in destabilization of their cor-
responding mRNAs are of prime importance (22, 31, 35).
Several reports have also suggested a relationship between the
relative affinity of a given RNA for RNA-binding protein(s)
and the stability of an mRNA containing these sequences (31,
35). Our preliminary results reveal that the CDR1 3 UTR is
FIG. 7. Cdr1p decay assay. (A) Exponentially grown cultures of C. albicans were translationally halted at 30°C by addition of 75 mM of
cycloheximide for 1 h. Whole-cell extracts were prepared at the indicated times after cycloheximide treatment. For AR isolates, 20 g, and for
AS isolates,30 g (because of relatively low expression of Cdr1p) of crude extract for each time was loaded and separated by SDS-polyacrylamide
gel electrophoresis. Equal loading of protein was assessed using a Coomassie-stained gel (data not shown). Cdr1p was detected using a polyclonal
anti-Cdr1p antibody. The Cdr1p-specific bands were subsequently quantified by densitometry scanning in a phosphorimager. (B) Band intensities
(represented as percentages of the value at T0) for each isolate were plotted against the chased time. t1/2, half-life.
1490 MANOHARLAL ET AL. ANTIMICROB. AGENTS CHEMOTHER.
78% AU rich and also possesses several putative consensus
binding sequences for a regulatory RNA-binding protein(s).
Therefore, any contribution of CDR1 3 UTR cis elements and
of the mutation or alteration in trans-acting regulatory fac-
tor(s) corresponding to these conserved elements in determin-
ing mRNA stability between AS and AR isolates requires an
in-depth analysis.
Our results with the reporter fusion transformants also sug-
gest that sequences in the CDR1 coding region could also be an
important contributor for increased CDR1 expression in AR
isolates. In this context, it should be mentioned that synony-
mous and nonsynonymous nucleotide polymorphisms have
been observed in the CDR1 coding region, but so far none of
these has been linked to CDR1 overexpression (12, 15). Our
present study did not consider the role of these allelic differ-
ences in sustained overexpression of CDR1 in AR isolates.
However, a recent study has reported that a silent polymor-
phism does not influence human P-gp/MDR1 mRNA and pro-
tein expression but affects posttranslational events in terms of
timing of cotranslational folding and membrane insertion
(19, 43).
In conclusion, our results demonstrate for the first time that
CDR1 is regulated by both transcriptional and posttranscrip-
tional events. Our finding that the acquisition of azole resis-
tance involves transcriptional activation as well as decreased
mRNA turnover opens up new possibilities for treatment re-
gimes to circumvent MDR in C. albicans. In this context, it is
worth mentioning that the intervention of overexpressing
MDR1 in MDR cell lines by verapamil (25) and ecteinascidin
743 (39) has been reported to be due to the transcriptional
down-regulation of the gene.
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